Polycystic Kidney, Autosomal Dominant

1

Review clinical trials related to Polycystic Kidney, Autosomal Dominant. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria. This trial tests if the SGLT2-inhibitor dapagliflozin slows down the loss of kidney function in ADPKD.

Participants needed: 420
Trial details
Phase: Phase 3Age: 18-60Biological sex: AllType: InterventionalSponsor: University of CologneUpdated: Jun 15, 2026Locations: 30
Eligibility criteria

Male and female patients with ADPKD (modified Ravine criteria) ≥ 18 and ≤ 60 yea... [+7]

Treatment with tolvaptan, somatostatin analogue, lithium or SGLT2i within the la... [+12]